Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma

3 Apr 2024

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with an overall 5-year survival rate of <12% due to the lack of effective treatments. Novel treatment strategies are urgently needed. Here, PKMYT1 is identified through genome-wide CRISPR screens as a non-mutant, genetic vulnerability of PDAC. Higher PKMYT1 expression levels indicate poor prognosis in PDAC patients. PKMYT1 ablation inhibits tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to CRISPR and Genetic Engineering
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38570712
DOI: 10.1038/s44321-024-00060-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinomaPMID 38570712Read ↗

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtypeSemantic proximity Read ↗

Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer.Semantic proximity Read ↗

Integrative genomic identification of therapeutic targets for pancreatic cancerSemantic proximity Read ↗

Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapySemantic proximity Read ↗

Clinical Significance of MTAP Deletion in Pancreatic Ductal Adenocarcinoma: A Real-World US Patient Cohort StudySemantic proximity Read ↗

Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethalitySemantic proximity Read ↗

Targeted Therapies in Pancreatic Cancer: A New Era of Precision MedicineSemantic proximity Read ↗

Large-scale multi-omic analysis identifies noncoding somatic driver mutations and nominates<i>ZFP36L2</i>as a driver gene for pancreatic ductal adenocarcinomaSemantic proximity Read ↗

MICAL2 Promotes Pancreatic Cancer Growth and MetastasisSemantic proximity Read ↗

TP53 missense–specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancerSemantic proximity Read ↗

Molecular mechanisms of RACK1-driven metastasis in pancreatic ductal adenocarcinoma revealed by single-cell RNA sequencingSemantic proximity Read ↗

PKM2 modulates chemotherapy sensitivity by regulating autophagy and predicts the prognosis and immunity in pancancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.